drugset
drugset / Trial / NCT02198287

Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

NCT02198287 ↗

Phase 1 Completed 54 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety, tolerability and pharmacokinetic study of BIIX 1 XX in healthy male volunteers.

Timeline

Start
1999-01
Primary completion
1999-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIX 1 XX Unknown 800 ug Inhaled
Subject BIIX 1 XX Unknown 1000 ug Inhaled
Subject BIIX 1 XX Unknown 1200 ug Inhaled
Subject BIIX 1 XX Unknown 1400 ug Inhaled
Subject BIIX 1 XX Unknown 1600 ug Inhaled
Subject BIIX 1 XX Unknown 1800 ug Inhaled
Subject BIIX 1 XX Unknown 2000 ug Inhaled

Indications

No indication recorded.